Loading...
Market
How will the market respond to Roche's acquisition of Poseida by March 31, 2025?
2
Resolution / Starting Odds
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
Stock market data and analysis from financial news sources
Story
Roche to Acquire Poseida Therapeutics for $9 Per Share Plus $4 CVR in $1.5 Billion CAR-T Deal
Nov 26, 2024, 06:45 AM
Roche Holding AG has entered into a definitive agreement to acquire California-based Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in CAR-T cell therapies, for $9 per share in cash, totaling $1 billion upfront. Shareholders will also receive a non-tradeable contingent value right (CVR) of up to $4 per share, bringing the total potential value of the deal to $1.5 billion. This transaction represents a significant premium of approximately 200% over Poseida's recent share price. The acquisition includes Poseida's cell therapy candidates and related platform technologies, which focus on developing off-the-shelf CAR-T therapies for the treatment of autoimmune diseases, hematological malignancies, and solid tumors.
View original story
Similar markets
Full $1.5 billion • 25%
$1.25 - $1.5 billion • 25%
$1 - $1.25 billion • 25%
Below $1 billion • 25%
Above $10 • 25%
$8-$10 • 25%
$6-$8 • 25%
Below $6 • 25%
Stock increases by over 5% • 33%
Stock remains within +/- 5% • 34%
Stock decreases by over 5% • 33%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Yes • 50%
No • 50%
Sarepta stock up >10% • 25%
Arrowhead stock up >10% • 25%
Both stocks up >10% • 25%
Neither stock up >10% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%